- Home
- LGI vs ARCT Comparison
LGI vs ARCT Comparison
Compare LGI & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGI | ARCT |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.8M | 189.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | LGI | ARCT |
|---|---|---|
| Price | $15.58 | $6.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $27.70 |
| AVG Volume (30 Days) | 51.3K | ★ 464.2K |
| Earning Date | 01-01-0001 | 03-03-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.95 | $5.85 |
| 52 Week High | $19.88 | $24.14 |
Technical Indicators
Market Signals| Indicator | LGI | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 24.22 | 42.90 |
| Support Level | N/A | $6.36 |
| Resistance Level | $17.75 | $7.88 |
| Average True Range (ATR) | 0.45 | 0.37 |
| MACD | -0.18 | -0.00 |
| Stochastic Oscillator | 1.82 | 22.60 |
Price Performance
Historical ComparisonAbout LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.